A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9–12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25126773 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Julieta Dominguez-Ortiz und 27 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, Universidad Nacional Autónom…. Hauptthemen laut MEDLINE: BRCA1 Protein, Alleles, Hereditary Breast and Ovarian Cancer Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Programa presupuestario Anexo 13 del Decreto de PEF: 309 Clínica de Cáncer Hereditario”, Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), Mexico.
Abstract (Originalsprache)
Hereditary breast and ovarian cancer (HBOC) syndrome is a genetic condition that increases the risk of breast cancer by 80% and that of ovarian cancer by 40%. The most common pathogenic variants (PVs) causing HBOC occur in the BRCA1 gene, with more than 3850 reported mutations in the gene sequence. The prevalence of specific PVs in BRCA1 has increased across populations due to the effect of founder mutations. Therefore, when a founder mutation is identified, it becomes key to improving cancer risk characterization and effective screening protocols. The only founder mutation described in the Mexican population is the deletion of exons 9 to 12 of BRCA1 (BRCA1Δ9–12), and its description focuses on the gene sequence, but no transcription profiles have been generated for individuals who carry this gene. In this study, we describe the transcription profiles of cancer patients and healthy individuals who were heterozygous for PV BRCA1Δ9–12 by analyzing the differential expression of both alleles compared with the homozygous BRCA1 control group using RT–qPCR, and we describe the isoforms produced by the BRCA1 wild-type and BRCA1Δ9–12 alleles using nanopore long-sequencing. Using the Kruskal–Wallis test, our results showed a similar transcript expression of the wild-type allele between the healthy heterozygous group and the homozygous BRCA1 control group. An association between the recurrence and increased expression of both alleles in HBOC patients was also observed. An analysis of the sequences indicated four wild-type isoforms with diagnostic potential for discerning individuals who carry the PV BRCA1Δ9–12 and identifying which of them has developed cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unidad de Investigación Biomédica en Cáncer, Instituto Nacional de Cancerología-Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), Avenida San Fernando No. 22 Col. Sección XVI, Tlal…
- Instituto Nacional de Cancerología, Universidad Nacional Autónoma de México (UNAM), Coyoacán, Mexico City 04510, Mexico.
- Clínica de Cáncer Hereditario, Instituto Nacional de Cancerología, Av. San Fernando No. 22 Col. Sección XVI, Tlalpan, Mexico City 14080, Mexico.
- Núcleo B de Innovación en Medicina de Precisión, Instituto Nacional de Medicina Genómica, Periférico Sur 4809, Arenal Tepepan, Tlalpan, Mexico City 14610, Mexico.
- Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, 2200 Copenhagen, Denmark.
- Instituto Nacional de Pediatría, Insurgentes Sur No. 3700-C. Coyoacán, Mexico City 04530, Mexico.
ORCID-Profile: Rogelio Montiel-Manríquez, Alberto Cedro-Tanda, Clementina Castro-Hernández, Laura Contreras-Espinosa, Leda Torres-Maldonado, Rodrigo González-Barrios, Ulises Juárez-Figueroa, Silvia Vidal-Millán, Abraham Pedroza-Torres, Sergio Nicasio-Arzeta, Fernando Luna, Fernanda Cisneros-Soberanis, Sara Frías, Luis A Herrera-Montalvo
Förderung
- “Programa presupuestario Anexo 13 del Decreto de PEF: 309 Clínica de Cáncer Hereditario”
- Consejo Nacional de Humanidades, Ciencias y Tecnologías (CONAHCYT), Mexico
Zitieren
APA
Dominguez-Ortiz, J., Álvarez-Gómez, R. M., Montiel-Manríquez, R., Cedro-Tanda, A., Alcaraz, N., Castro-Hernández, C., Bautista-Hinojosa, L., Contreras-Espinosa, L., Torres-Maldonado, L., Fragoso-Ontiveros, V., Sánchez-Contreras, Y., González-Barrios, R., Fuente-Hernández, M. A., Mejía-Aguayo, M. L., Juárez-Figueroa, U., Padua-Bracho, A., Sosa-León, R., Obregon-Serrano, G., Vidal-Millán, S., …, & Herrera-Montalvo, L. A. (2024). A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9–12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126773
Vancouver
Dominguez-Ortiz J, Álvarez-Gómez RM, Montiel-Manríquez R, Cedro-Tanda A, Alcaraz N, Castro-Hernández C, et al. A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9–12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126773
BibTeX
@article{DominguezOrtiz2024,
author = {Dominguez-Ortiz, Julieta and Álvarez-Gómez, Rosa M and Montiel-Manríquez, Rogelio and Cedro-Tanda, Alberto and Alcaraz, Nicolás and Castro-Hernández, Clementina and Bautista-Hinojosa, Luis and Contreras-Espinosa, Laura and Torres-Maldonado, Leda and Fragoso-Ontiveros, Verónica and Sánchez-Contreras, Yuliana and González-Barrios, Rodrigo and Fuente-Hernández, Marcela Angélica De la and Mejía-Aguayo, María de la Luz and Juárez-Figueroa, Ulises and Padua-Bracho, Alejandra and Sosa-León, Rodrigo and Obregon-Serrano, Gabriela and Vidal-Millán, Silvia and Núñez-Martínez, Paulina María and Pedroza-Torres, Abraham and Nicasio-Arzeta, Sergio and Rodríguez, Alfredo and Luna, Fernando and Cisneros-Soberanis, Fernanda and Frías, Sara and Arriaga-Canon, Cristian and Herrera-Montalvo, Luis A},
title = {A Molecular Characterization of the Allelic Expression of the BRCA1 Founder Δ9–12 Pathogenic Variant and Its Potential Clinical Relevance in Hereditary Cancer},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25126773}
}
EUVIMED